Saturday, October 16, 2021

FDA approves Janssen’s Rybrevant




The US Food and Drug Administration (FDA) has approved Janssen’s Rybrevant as the first treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

In the US, currently available targeted treatments such as EGFR tyrosine kinase inhibitors (TKIs) are not FDA-approved for treating NSCLC driven by EGFR exon 20 insertion mutations.

On top of that, NSCLC driven by this particular mutation often carries a worse prognosis and reduced survival rates compared with lung cancer driven by more common mutations.

“The approval of Rybrevant, along with the companion diagnostic test, addresses high unmet need in the treatment of people with genetically defined non-small cell lung cancer,” said Peter Lebowitz, global therapeutic area head, oncology, Janssen Research & Development.

“At Janssen, we are committed to the development of innovative therapies like Rybrevant and believe that advancing medicines targeting specific pathways can bring the greatest benefits and improve outcomes for patients with tumour alterations such as EGFR and MET,” he added.

Rybrevant, a fully-human bispecific antibody, is designed to directly target EGFR and MET receptors.

The FDA approval is based on positive data from the Phase I Chrysalis study, in which Rybrevant-treated patients achieved an overall response rate of 40%, with 4% of patients having complete response and 36% achieving partial responses.

These responses were found to be durable, with median duration of response of 11.1 months, with 20% having responses of at least six months or greater duration.

The median progression-free survival (PFS) was 8.3 months and median overall survival (OS) was 22.8 months.

“Today’s FDA approval is an important development for people living with non-small cell lung cancer with exon 20 insertion mutations who, until now, have had no approved treatment options to target their disease,” said Jill Feldman, co-founder of the EGFR Resisters, an advocacy organisation patient group, and a lung cancer patient advocate.

“We are excited by the promise this new treatment option brings to people with this particular type of lung cancer and their families,” she added.



Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...